(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
In the year since the Humira biosimilar floodgates opened, AbbVie’s star immunology player has proven tough to drown out. In a new effort to crack the popular immunology drug’s 82% grasp on the market ...
(Reuters) - CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results